---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-001673"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:46:24.041600+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entera Bio Q1 net loss $2.6M ($0.06/sh); cash runway to mid-Q3 2026; pipeline advances

## Summary
- Net loss of $2.6M ($0.06 per share) for Q1 2025 vs $2.0M ($0.05) in Q1 2024; operating expenses $2.6M.
- Cash and equivalents $20.6M as of Mar 31, 2025; expects to fund operations through mid-Q3 2026.
- EB613 (oral PTH) bone data presented at WCO-IOF-ESCEO Apr 2025; Next Gen EB613 Phase 1 planned H2 2025.
- Collaboration with OPKO for oral GLP-1/Glucagon program; IND filing planned late 2025/early 2026.
- Appointed Cherin Smith as EVP Clinical Ops (Mar) and Leslie Gautam as CBO (May 2025).

## SEC filing metadata
- accession: 0001178913-25-001673
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891325001673/0001178913-25-001673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891325001673/zk2533149.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-001673
- JSON: https://secwatch.observer/filing/0001178913-25-001673.json
- Plain text: https://secwatch.observer/filing/0001178913-25-001673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.